B cells and antibodies in MS

Results and Problems in Cell Differentiation

Volumn 51, Issue , 2010, Pages 99-113

  Reindl, Markus ^a   Kuenz, Bettina ^a   Berger, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; IMMUNOGLOBULIN G; MYELIN ASSOCIATED GLYCOPROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; VIRUS ANTIBODY; MOG PROTEIN, HUMAN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BIOLOGICAL MODEL; BIOSYNTHESIS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATHOLOGY;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; AQUAPORIN 4; AUTOANTIBODIES; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROMYELITIS OPTICA; MYELIN PROTEINS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 77956914021     PISSN: 00801844     EISSN: 18610412     Source Type: Book Series    
DOI: 10.1007/400_2008_16     Document Type: Article

References (102)

1. Allen CD et al. (2004) Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 5:943-952
2. Ansel KM et al. (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406:309-314
3. Arce S et al. (2002)wThe role of long-lived plasma cells in autoimmunity. Immunobiology 206:558-562
4. Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61:288-299
5. Bar-Or A et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395-400
6. Baranzini SE et al. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163:5133-5144
7. Berger T et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139-145
8. Bernasconi NL et al. (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202
9. Bray PF et al. (1992) Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42:1798-1804
10. Breij EC et al. (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63:16-25
11. Brunner C et al. (1989) Differential ultrastructural localization of myelin basic protein, myelin/ oligodendroglial glycoprotein, and 2'́,3'́-cyclic nucleotide 3'́-phosphodiesterase in the CNS of adult rats. J Neurochem 52:296-2304
12. Cepok S et al. (2001) Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124:2169-2176
13. Cepok S et al. (2003) The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol 60:849-855
14. Cepok S et al. (2005a) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667-1676
15. Cepok S et al. (2005b) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115:1352-1360
16. Cepok S et al. (2006) Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol 180:33-39
17. Cepok S et al. (2007) Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol 62:458-467
18. Colombo M et al. (2000) Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 164:2782-2789
19. Corcione A et al. (2004) Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 101:11064-11069
20. Cree BA et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
21. Cross AH et al. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63-70
22. Dal Bianco A et al. (2008) Multiple sclerosis and Alzheimer's disease. Ann Neurol 63:174-183
23. DeLorenze GN et al. (2006) Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63:839-844
24. Freedman MS et al. (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62:865-870
25. Gaertner S et al. (2004) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63:2381-2383
26. Genain CP et al. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-175
27. Greeve I et al. (2007) Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 116:207-210
28. Gunn MD et al. (1998) A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391:799-803
29. Haahr S, Hollsberg P (2006) Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 16:297-310
30. Hansen K et al. (1990) Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 161:1194-1202
31. Hauser SL et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688
32. Hollsberg P et al. (2003) Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 132:137-143
33. Ishizu T et al. (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128:988-1002
34. Jarius S et al. (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076-1077
35. Kabat EA et al. (1948) Quantitative estimation of the albumin and gamma-globulin in normal and pathological cerebrospinal fluid by immunochemical methods. Am J Med 4:653-662
36. Keegan M et al. (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143-146
37. Keegan M et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579-582
38. Kerlero de Rosbo N et al. (1990) Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 55:583-587
39. Krumbholz M et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195-200
40. Krumbholz M et al. (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129:200-211
41. Kuenz B et al. (2008) Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PloSONE 3(7):e2559
42. Kuhle J et al (2007a) Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 254:160-168
43. Kuhle J et al. (2007b) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356:371-378
44. Lalive PH et al. (2006) Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 103:2280-2285
45. Lennon VA et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106-2112
46. Lennon VA et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473-477
47. Levin LI et al. (2005) Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293:2496-2500
48. Lim ET et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11:492-494
49. Lindert RB et al. (1999) Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122(Pt 11):2089-2100
50. Linington C et al. (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443-454
51. Link H, Huang YM (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180:17-28
52. Lucchinetti CF et al. (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274
53. Lucchinetti C et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
54. Lucchinetti CF et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-1461
55. Lunemann JD et al. (2006) Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129:1493-1506
56. Luther SA et al. (2003) Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J Exp Med 197:1191-1198
57. MacLennan IC (1994) Germinal centers. Annu Rev Immunol 12:117-139
58. Magliozzi R et al. (2004) Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148:11-23
59. Magliozzi R et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089-1104
60. Manz RA et al. (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14:517-521
61. Manz RA et al. (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23:367-386
62. Marignier R et al. (2008) NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 14:440-445
63. Marta CB et al. (2005) Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 102:13992-13997
64. Matsuoka T et al. (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130:1206-1223
65. McDonald WI et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
66. Misu T et al. (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130:1224-1234
67. Moldenhauer A et al. (2005) Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 35:523-530
68. O'Connor KC et al. (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211-217
69. Owens GP et al. (1998) Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 43:236-243
70. Owens GP et al. (2003) Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 171:2725-2733
71. Paul F et al. (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133
72. Pelayo R et al. (2007) Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 356:426-428
73. Pohl D et al. (2006) High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67:2063-2065
74. Rauer S et al. (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psych 77:739-742.
75. Reff ME et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
76. Reiber H (1998) Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4:99-107
77. Reindl M et al. (2006) Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 180:50-62
78. Roemer SF et al. (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130:1194-1205
79. Serafini B et al. (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174
80. Serafini B et al. (2007) Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899-2912
81. Shapiro-Shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5:230-242
82. Sharief MK, Thompson EJ (1991) Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 114(Pt 1A):181-195
83. Sharief MK et al. (1990) Intrathecal synthesis of IgM in neurological diseases: a comparison between detection of oligoclonal bands and quantitative estimation. J Neurol Sci 96:131-142
84. Storch MK et al. (1998) Multiple sclerosis: in situ evidence for antibody- and complementmediated demyelination. Ann Neurol 43:465-471
85. Takahashi T et al. (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235-1243
86. Thacker EL et al. (2006) Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59:499-503
87. Tomassini V et al. (2007) Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 13:1086-1094
88. Uccelli A et al. (2005) Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol 26:254-259
89. Villar LM et al. (2002) Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59:555-559
90. Villar LM et al. (2003) Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53:222-226
91. Wandinger K et al. (2000) Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55:178-184
92. Wang LY, Fujinami RS (1997) Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol 75:75-83
93. Wang H et al. (2008) Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 71:1142-1146
94. Weinshenker BG et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878-886
95. Weinshenker BG et al. (2006a) NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 22:197-206
96. Weinshenker BG et al. (2006b) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566-569
97. Wingerchuk DM et al. (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53:1107-1114
98. Wingerchuk DM et al. (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485-1489
99. Winges KM et al. (2007) Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J Neuroimmunol 192:226-234
100. Wucherpfennig KW et al. (1997) Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 100:1114-1122
101. Yu P et al. (2002) B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion. J Immunol 168:5117-5123
102. Zhou D et al. (2006) Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 103:19057-19062